Hana Biosciences’ clinical trial agreement with the National Cancer Institute

Business of Biotech

Hana Biosciences (OTCBB:HNAB) announced a Clinical Trial Agreement with the Center for Cancer Research (CCR) at the National Cancer Institute for the co-development of Marqibo(R) (vincristine sulfate liposomes injection) in refractory pediatric cancer. The five-year agreement will initially focus on a Phase 1 trial to evaluate the safety, preliminary efficacy, pharmacokinetic profile, and weekly dose of Marqibo in children and adolescents with refractory cancer. Following the Phase I trial, the Company and CCR plan a Phase 2 trial in pediatric acute lymphoblastic leukemia, the most common cancer of childhood. The Company anticipates that this Phase 2 trial will facilitate subsequent studies of Marqibo in combination with standard chemotherapy regimens.

Read the release.

Business of Biotech  |  Email This Post  |  Printer Friendly
Tags: ,

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>